134 related articles for article (PubMed ID: 36337904)
1. Long coverage with drug-eluting stents is superior to spot coverage for long femoropopliteal artery disease: PARADE II study.
Park JI; Ko YG; Lee YJ; Lee SJ; Hong SJ; Ahn CM; Kim JS; Kim BK; Hong MK; Yu CW; Rha SW; Park JK; Min PK; Yoon CH; Lee SR; Park SH; Choi DH
Front Cardiovasc Med; 2022; 9():1022071. PubMed ID: 36337904
[TBL] [Abstract][Full Text] [Related]
2. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
[TBL] [Abstract][Full Text] [Related]
3. Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease.
Bausback Y; Wittig T; Schmidt A; Zeller T; Bosiers M; Peeters P; Brucks S; Lottes AE; Scheinert D; Steiner S
J Am Coll Cardiol; 2019 Feb; 73(6):667-679. PubMed ID: 30765033
[TBL] [Abstract][Full Text] [Related]
4. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
5. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
6. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
[TBL] [Abstract][Full Text] [Related]
7. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
8. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness Study of Drug-Eluting and Bare-Metal Peripheral Artery Stents in Endovascular Femoropopliteal Artery Revascularization.
Jeon-Slaughter H; Khalili H; Tsai S; Armstrong EJ; Shammas NW; Jawaid O; Lu H; Addo T; Gigliotti O; Abu-Fadel M; Banerjee S
J Invasive Cardiol; 2018 Oct; 30(10):373-379. PubMed ID: 30279293
[TBL] [Abstract][Full Text] [Related]
10. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease.
Ko YG; Ahn CM; Rha SW; Yu CW; Park SH; Lee SJ; Lee JH; Her SH; Kang WC; Cho YS; Seo JB; Cho YH; Choi D;
Ann Vasc Surg; 2019 Jul; 58():101-107. PubMed ID: 30769056
[TBL] [Abstract][Full Text] [Related]
13. Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience.
Lee YJ; Kook H; Ko YG; Yu CW; Joo HJ; Ahn CM; Choi D
Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):287-295. PubMed ID: 33223281
[TBL] [Abstract][Full Text] [Related]
14. Comparison of full lesion coverage versus spot drug-eluting stent implantation for coronary artery stenoses.
Kim S; Yun KH; Kang WC; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Yonsei Med J; 2014 May; 55(3):584-91. PubMed ID: 24719123
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
[TBL] [Abstract][Full Text] [Related]
16. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
[TBL] [Abstract][Full Text] [Related]
17. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Zeller T; Roubin GS; Burket MW; Khatib Y; Snyder SA; Ragheb AO; White JK; Machan LS;
Circ Cardiovasc Interv; 2011 Oct; 4(5):495-504. PubMed ID: 21953370
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study.
Liistro F; Angioli P; Porto I; Ducci K; Falsini G; Ventoruzzo G; Ricci L; Scatena A; Grotti S; Bolognese L
J Am Coll Cardiol; 2019 Jul; 74(2):205-215. PubMed ID: 31296293
[TBL] [Abstract][Full Text] [Related]
20. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
